Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 28 Researches
7.7
USERS' SCORE
Moderately Good
Based on 10 Reviews
7.7
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Wild Caught Fish Oil Concentrate
1250 mg
†
Total Omega-3 Fatty Acids as TG
1055 mg
†
EPA (Eicosapentaenoic Acid)
690 mg
†
DHA (Docosahexaenoic Acid)
310 mg
†
Other Omega-3 Fatty Acids
55 mg
†
Top Medical Research Studies
9
We investigated the potential of DHA-enriched phosphatidylserine (DHA-PS) in addressing liver injuries caused by cyclophosphamide in mice. By administering cyclophosphamide over five days, we created a model to simulate this liver damage. Following this, we treated the mice with different doses of DHA-PS for a week to see if it could help heal their livers.
Our findings were quite promising. The mice receiving DHA-PS experienced significant improvements in key liver health indicators, including reduced inflammation and oxidative stress. Through advanced analysis, we discovered that DHA-PS helped correct metabolic imbalances caused by cyclophosphamide, which is a crucial aspect of liver recovery.
Additionally, we observed that DHA-PS has a positive impact on the gut-liver axis. This treatment restored the intestinal barrier, reduced harmful compounds in the bloodstream, and improved overall gut microbiota health. By balancing the gut bacteria, we enhanced the overall health of the mice.
Overall, the results suggest that DHA-PS could be a valuable therapeutic option or functional food for combating liver injuries related to cyclophosphamide. This study highlights the potential benefits of DHA on liver health and underscores the importance of the gut-liver connection.
Our findings were quite promising. The mice receiving DHA-PS experienced significant improvements in key liver health indicators, including reduced inflammation and oxidative stress. Through advanced analysis, we discovered that DHA-PS helped correct metabolic imbalances caused by cyclophosphamide, which is a crucial aspect of liver recovery.
Additionally, we observed that DHA-PS has a positive impact on the gut-liver axis. This treatment restored the intestinal barrier, reduced harmful compounds in the bloodstream, and improved overall gut microbiota health. By balancing the gut bacteria, we enhanced the overall health of the mice.
Overall, the results suggest that DHA-PS could be a valuable therapeutic option or functional food for combating liver injuries related to cyclophosphamide. This study highlights the potential benefits of DHA on liver health and underscores the importance of the gut-liver connection.
Read More
9
We explored the impact of docosahexaenoic acid (DHA), a type of omega-3 fatty acid, on the health of our liver, especially regarding nonalcoholic fatty liver disease (NAFLD). Using a zebrafish model with a specific mutation that prevents the production of DHA, we aimed to understand how this absence affects liver lipid balance and overall liver health.
Our findings revealed that without sufficient DHA, the liver showed increased fat storage and issues with fat processing. Instead of breaking down fats as it should, the liver was overwhelmed with lipids, leading to the telltale signs of NAFLD. Additionally, we noted that the liver cells in our mutated model were suffering from structural damage and stress, primarily through a process known as ferroptosis—rather than the more commonly known apoptosis.
Interestingly, when we supplemented these fish with DHA through diet or genetic modifications, we observed a remarkable improvement in liver health. This suggests that maintaining proper levels of DHA is crucial for preventing fatty liver disease and protecting liver cells from damage.
Our findings revealed that without sufficient DHA, the liver showed increased fat storage and issues with fat processing. Instead of breaking down fats as it should, the liver was overwhelmed with lipids, leading to the telltale signs of NAFLD. Additionally, we noted that the liver cells in our mutated model were suffering from structural damage and stress, primarily through a process known as ferroptosis—rather than the more commonly known apoptosis.
Interestingly, when we supplemented these fish with DHA through diet or genetic modifications, we observed a remarkable improvement in liver health. This suggests that maintaining proper levels of DHA is crucial for preventing fatty liver disease and protecting liver cells from damage.
Read More
8
We investigated how eicosapentaenoic acid (EPA), derived from the marine microalgae Nannochloropsis oceanica, affects liver disease, particularly focusing on its potential to address liver fibrosis in rats. In a structured study, we divided the rats into groups that received varying doses of the EPA-rich algae alongside a control group given fish oil, known for its omega-3 content.
Our research revealed that the rats fed with the highest dose of the N. oceanica biomass experienced marked improvements. The serum levels of liver enzymes and cholesterol, which typically rise due to liver damage, saw a significant decline in those rats. We also noted that the histological examinations indicated less inflammation and lesser damage to liver cells in the groups consuming the algal biomass.
Additionally, the study showed positive changes in gut microbiota. We observed an increase in beneficial bacteria associated with short-chain fatty acid production in the groups fed with EPA. This suggests that not only does EPA help with liver health, but it might also positively influence gut health.
Ultimately, our findings suggest that N. oceanica biomass, with its high EPA content, can be an effective supplement for reducing liver fibrosis, offering an alternative to traditional fish oil in promoting liver health.
Our research revealed that the rats fed with the highest dose of the N. oceanica biomass experienced marked improvements. The serum levels of liver enzymes and cholesterol, which typically rise due to liver damage, saw a significant decline in those rats. We also noted that the histological examinations indicated less inflammation and lesser damage to liver cells in the groups consuming the algal biomass.
Additionally, the study showed positive changes in gut microbiota. We observed an increase in beneficial bacteria associated with short-chain fatty acid production in the groups fed with EPA. This suggests that not only does EPA help with liver health, but it might also positively influence gut health.
Ultimately, our findings suggest that N. oceanica biomass, with its high EPA content, can be an effective supplement for reducing liver fibrosis, offering an alternative to traditional fish oil in promoting liver health.
Read More
Most Useful Reviews
9
Liver index declining
I initially took this to alleviate dry eye syndrome, recommended by my doctor. While that didn't improve much, I did notice my liver index decreased significantly after consuming one can (90 pills). My total cholesterol varied slightly. I plan to continue with the next can and monitor for any further changes over three months.
Read More
9
Protects liver health
It promotes the formation of prostaglandins, protecting the liver from inflammation, normalising glycogen synthesis, and reducing the risk of developing conditions such as fibrosis and cirrhosis.
Read More
6
No fishy aftertaste
337 people found this helpful
The key benefit of this omega is that it contains fish oil in the form of triglycerides. The label indicates this, confirming that it’s derived from fish carcasses rather than liver, which can accumulate toxins. I take one capsule each morning with my husband during breakfast. Unlike other brands, there’s no fishy aftertaste. My skin feels moisturised, and I have noticed reduced peeling. I recommend this product for its quality and effectiveness.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 28 Researches
7.7
- All Researches
9
We explored the effectiveness of eicosapentaenoic acid (EPA), a key component of Antarctic krill oil, in battling obesity and its associated liver issues. Our investigation specifically aimed to understand how EPA influences cholesterol levels and overall liver health, especially in the context of diet-induced obesity.
Using a mouse model and analyzing various molecular pathways, we observed that a high-fat diet led to increased oxidative stress and obesity-related indicators, which are harmful to liver function. However, the introduction of EPA showed promising results in reducing oxidative stress, fat accumulation, and improving key metabolic parameters. These improvements were linked to better cholesterol management and support for liver health.
The findings suggest that EPA might serve as a valuable intervention for those struggling with obesity-related liver disease. By enhancing cholesterol metabolism and addressing oxidative stress, EPA could play a role in the prevention and treatment of these conditions. Overall, our results indicate a potential pathway for therapeutic applications in liver health through EPA supplementation.
Using a mouse model and analyzing various molecular pathways, we observed that a high-fat diet led to increased oxidative stress and obesity-related indicators, which are harmful to liver function. However, the introduction of EPA showed promising results in reducing oxidative stress, fat accumulation, and improving key metabolic parameters. These improvements were linked to better cholesterol management and support for liver health.
The findings suggest that EPA might serve as a valuable intervention for those struggling with obesity-related liver disease. By enhancing cholesterol metabolism and addressing oxidative stress, EPA could play a role in the prevention and treatment of these conditions. Overall, our results indicate a potential pathway for therapeutic applications in liver health through EPA supplementation.
Read More
9
We conducted an intriguing study to explore the effects of tyrosol (TYR), a compound enriched with beneficial properties, on nonalcoholic fatty liver disease (NAFLD) in mice. Males of the C57BL/6J strain were divided into groups that received either a low-fat diet, a high-fat diet, or a high-fat diet supplemented with 0.025% TYR for 16 weeks.
Observations revealed that the mice consuming the TYR-enriched diet experienced a notable decrease in both final body weight and liver fat accumulation compared to those on just the high-fat diet. A closer examination of liver metabolites showed an increase in key substances, including eicosapentaenoic acid (EPA), which suggests that TYR positively influences lipid metabolism and supports liver health.
We further investigated the mechanism behind these benefits and found that TYR interacts with a receptor known as peroxisome proliferator-activated receptor-alpha (PPARα). This interaction is crucial in regulating liver lipid processing, helping to turn on the genes that promote better lipid management.
Overall, this compelling evidence indicates that TYR, particularly through its role involving EPA and PPARα, could be a promising dietary addition for alleviating fatty liver disease in contexts of poor diets. We are excited about these insights and their potential implications for improving liver health.
Observations revealed that the mice consuming the TYR-enriched diet experienced a notable decrease in both final body weight and liver fat accumulation compared to those on just the high-fat diet. A closer examination of liver metabolites showed an increase in key substances, including eicosapentaenoic acid (EPA), which suggests that TYR positively influences lipid metabolism and supports liver health.
We further investigated the mechanism behind these benefits and found that TYR interacts with a receptor known as peroxisome proliferator-activated receptor-alpha (PPARα). This interaction is crucial in regulating liver lipid processing, helping to turn on the genes that promote better lipid management.
Overall, this compelling evidence indicates that TYR, particularly through its role involving EPA and PPARα, could be a promising dietary addition for alleviating fatty liver disease in contexts of poor diets. We are excited about these insights and their potential implications for improving liver health.
Read More
9
Eicosapentaenoic Acid Reduces Hepatic Inflammation
We explored the impact of eicosapentaenoic acid (EPA) and other omega-3 polyunsaturated fatty acids (n-3 PUFA) on liver inflammation related to inflammatory bowel disease (IBD). Using a transgenic mouse model known as fat-1 mice, we saw how increased levels of n-3 PUFA in tissues could play a role in reducing liver damage associated with colitis.
Our study pointed out that those fat-1 mice experienced less severe liver inflammation and oxidative stress compared to wild-type mice when subjected to a chemical that induces colitis. This is significant because while many discussions around omega-3 fatty acids center on their benefits for gut health, our findings suggest they also hold promise in addressing liver complications that might arise due to gut inflammation.
Additionally, we observed notable increases in certain beneficial metabolites derived from EPA, which are linked to reducing inflammation. These findings underline a strong connection between dietary n-3 PUFA intake and less oxidative stress in the liver, which could open up new avenues for therapeutic approaches in managing IBD and its systemic effects.
Our study pointed out that those fat-1 mice experienced less severe liver inflammation and oxidative stress compared to wild-type mice when subjected to a chemical that induces colitis. This is significant because while many discussions around omega-3 fatty acids center on their benefits for gut health, our findings suggest they also hold promise in addressing liver complications that might arise due to gut inflammation.
Additionally, we observed notable increases in certain beneficial metabolites derived from EPA, which are linked to reducing inflammation. These findings underline a strong connection between dietary n-3 PUFA intake and less oxidative stress in the liver, which could open up new avenues for therapeutic approaches in managing IBD and its systemic effects.
Read More
9
We explored the effects of docosahexaenoic acid (DHA) on liver disease, specifically looking at its role in nonalcoholic fatty liver disease (NAFLD) and its potential connection to Alzheimer's disease. Our study conducted on APP/PS1 mice involved four groups of animals fed different diets—one with DHA, one with medium-chain triglycerides (MCTs), and one that combined both treatments.
Throughout the study, which lasted eight months, we observed a significant reduction in blood and liver lipids in the group that received both DHA and MCTs. This combination not only alleviated signs of NAFLD but also reduced the buildup of amyloid-β (Aβ), a protein linked to Alzheimer's, in the brain and serum.
Additionally, our findings indicated that DHA combined with MCTs improved the activity of liver enzymes critical for lipid metabolism. This suggests that these compounds together may enhance the liver's ability to clear fat and cholesterol while also increasing Aβ clearance.
While we noted the benefits of DHA, it's important to remember that the effects we observed were influenced by the combination with MCTs, making it challenging to pinpoint DHA's isolated impact. Still, our research provides valuable insight into how enhancing dietary fats could support liver health and potentially mitigate connections to neurodegenerative diseases.
Throughout the study, which lasted eight months, we observed a significant reduction in blood and liver lipids in the group that received both DHA and MCTs. This combination not only alleviated signs of NAFLD but also reduced the buildup of amyloid-β (Aβ), a protein linked to Alzheimer's, in the brain and serum.
Additionally, our findings indicated that DHA combined with MCTs improved the activity of liver enzymes critical for lipid metabolism. This suggests that these compounds together may enhance the liver's ability to clear fat and cholesterol while also increasing Aβ clearance.
While we noted the benefits of DHA, it's important to remember that the effects we observed were influenced by the combination with MCTs, making it challenging to pinpoint DHA's isolated impact. Still, our research provides valuable insight into how enhancing dietary fats could support liver health and potentially mitigate connections to neurodegenerative diseases.
Read More
9
We explored the effectiveness of docosahexaenoic acid (DHA), particularly when delivered via nanoparticles, in treating liver disease, specifically hepatocellular carcinoma (HCC), in three rodent models. Our focus was on understanding how DHA affects HCC lesions as well as the performance of weighted amide proton transfer (APT) MRI as a monitoring tool.
In all three models—diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft—the APT MRI revealed higher signals from the cancerous tissue compared to surrounding normal tissue. Notably, in the DEN model, we found that the APT signal could effectively differentiate between malignant lesions and benign nodules.
After administering LDL-DHA nanoparticles directly into tumors, we observed a rapid decrease in APT signals within 72 hours, suggesting a promising therapeutic response. This trend was consistent in both N1S1 and HepG2 xenografts, indicating that DHA's effects, accelerated by nanoparticles, hold potential for therapeutic applications in liver cancer management.
Overall, our findings underscore the utility of APT imaging in the diagnostic and therapeutic landscapes of HCC, showcasing how innovative delivery methods can enhance treatment outcomes.
In all three models—diethylnitrosamine (DEN) induced HCC, N1S1 syngeneic orthotopic xenograft, and human HepG2 ectopic xenograft—the APT MRI revealed higher signals from the cancerous tissue compared to surrounding normal tissue. Notably, in the DEN model, we found that the APT signal could effectively differentiate between malignant lesions and benign nodules.
After administering LDL-DHA nanoparticles directly into tumors, we observed a rapid decrease in APT signals within 72 hours, suggesting a promising therapeutic response. This trend was consistent in both N1S1 and HepG2 xenografts, indicating that DHA's effects, accelerated by nanoparticles, hold potential for therapeutic applications in liver cancer management.
Overall, our findings underscore the utility of APT imaging in the diagnostic and therapeutic landscapes of HCC, showcasing how innovative delivery methods can enhance treatment outcomes.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 10 Reviews
7.7
- All Reviews
- Positive Reviews
- Negative Reviews
9
Liver index declining
I initially took this to alleviate dry eye syndrome, recommended by my doctor. While that didn't improve much, I did notice my liver index decreased significantly after consuming one can (90 pills). My total cholesterol varied slightly. I plan to continue with the next can and monitor for any further changes over three months.
Read More
9
Protects liver health
It promotes the formation of prostaglandins, protecting the liver from inflammation, normalising glycogen synthesis, and reducing the risk of developing conditions such as fibrosis and cirrhosis.
Read More
6
No fishy aftertaste
337 people found this helpful
The key benefit of this omega is that it contains fish oil in the form of triglycerides. The label indicates this, confirming that it’s derived from fish carcasses rather than liver, which can accumulate toxins. I take one capsule each morning with my husband during breakfast. Unlike other brands, there’s no fishy aftertaste. My skin feels moisturised, and I have noticed reduced peeling. I recommend this product for its quality and effectiveness.
Read More
8
Beneficial for liver health
191 people found this helpful
This omega is highly effective and competes well against other brands like Solgar in terms of concentration and quality. I find it particularly beneficial for anyone with elevated platelets and liver enzymes. I’ve assessed this product’s value based on its benefits. It’s a necessary supplement that can be used long-term, making it a smart choice among high-quality options.
Read More
7.5
Reduces triglycerides
1 people found this helpful
Long-term use proves very beneficial in reducing triglycerides and managing fatty liver.
Read More
Frequently Asked Questions
9
Liver index declining
I initially took this to alleviate dry eye syndrome, recommended by my doctor. While that didn't improve much, I did notice my liver index decreased significantly after consuming one can (90 pills). My total cholesterol varied slightly. I plan to continue with the next can and monitor for any further changes over three months.
7.5
Reduces triglycerides
1 people found this helpful
Long-term use proves very beneficial in reducing triglycerides and managing fatty liver.
6
No fishy aftertaste
337 people found this helpful
The key benefit of this omega is that it contains fish oil in the form of triglycerides. The label indicates this, confirming that it’s derived from fish carcasses rather than liver, which can accumulate toxins. I take one capsule each morning with my husband during breakfast. Unlike other brands, there’s no fishy aftertaste. My skin feels moisturised, and I have noticed reduced peeling. I recommend this product for its quality and effectiveness.
7.5
Liver enzymes improved
38 people found this helpful
This omega product competes strongly with Solgar for both concentration and quality. It’s particularly beneficial for those with elevated platelets and liver enzymes. It's a vital supplement that can be taken continuously. I've evaluated the cost-benefit of various iHerb omega products, aiming for the most profitable option without compromising quality.
6
High-quality supplement
1 people found this helpful
I didn’t anticipate such good quality. I tried it, liked it, and now I only take it alongside lecithin and taurine for liver support.
8
Beneficial for liver health
191 people found this helpful
This omega is highly effective and competes well against other brands like Solgar in terms of concentration and quality. I find it particularly beneficial for anyone with elevated platelets and liver enzymes. I’ve assessed this product’s value based on its benefits. It’s a necessary supplement that can be used long-term, making it a smart choice among high-quality options.
7.5
Reduced cholesterol
2 people found this helpful
The quality of this Omega 3 is excellent, featuring clean ingredients. My health has significantly improved since taking it. The natural fish aids my body, and the packaging is convenient. My cholesterol has decreased, and there's less hair fall since I began using it. For optimal benefits, I recommend selecting fish oil in triglyceride form to ensure better absorption.
8
We investigated how eicosapentaenoic acid (EPA), derived from the marine microalgae Nannochloropsis oceanica, affects liver disease, particularly focusing on its potential to address liver fibrosis in rats. In a structured study, we divided the rats into groups that received varying doses of the EPA-rich algae alongside a control group given fish oil, known for its omega-3 content.
Our research revealed that the rats fed with the highest dose of the N. oceanica biomass experienced marked improvements. The serum levels of liver enzymes and cholesterol, which typically rise due to liver damage, saw a significant decline in those rats. We also noted that the histological examinations indicated less inflammation and lesser damage to liver cells in the groups consuming the algal biomass.
Additionally, the study showed positive changes in gut microbiota. We observed an increase in beneficial bacteria associated with short-chain fatty acid production in the groups fed with EPA. This suggests that not only does EPA help with liver health, but it might also positively influence gut health.
Ultimately, our findings suggest that N. oceanica biomass, with its high EPA content, can be an effective supplement for reducing liver fibrosis, offering an alternative to traditional fish oil in promoting liver health.
Our research revealed that the rats fed with the highest dose of the N. oceanica biomass experienced marked improvements. The serum levels of liver enzymes and cholesterol, which typically rise due to liver damage, saw a significant decline in those rats. We also noted that the histological examinations indicated less inflammation and lesser damage to liver cells in the groups consuming the algal biomass.
Additionally, the study showed positive changes in gut microbiota. We observed an increase in beneficial bacteria associated with short-chain fatty acid production in the groups fed with EPA. This suggests that not only does EPA help with liver health, but it might also positively influence gut health.
Ultimately, our findings suggest that N. oceanica biomass, with its high EPA content, can be an effective supplement for reducing liver fibrosis, offering an alternative to traditional fish oil in promoting liver health.
7
We aimed to understand how eicosapentaenoic acid (EPA), an omega-3 fatty acid, impacts liver health in individuals struggling with obesity. To do this, we conducted a study involving patients with obesity, specifically those with a body mass index (BMI) of 40 kg/m² or higher. Over the course of eight weeks, these participants received either 3.36 grams of n-3 PUFAs, which included 1.84 grams of EPA and 1.53 grams of docosahexaenoic acid (DHA), or a control of 5 grams of butter.
Afterward, as part of their pre-bariatric surgery routine, we collected liver biopsies to analyze gene expression changes. Utilizing Gene Set Enrichment Analysis (GSEA), we identified 80 significantly altered pathways linked to crucial functions such as metabolism and immune response. Notably, EPA treatment improved pathways involved in immune functions and lipid metabolism, while it decreased those associated with glucagon signaling.
Our findings underscore the potential of eicosapentaenoic acid to affect metabolic and immune processes in the liver of obese patients. This research paves the way for further exploration of EPA’s benefits and its role in addressing liver conditions associated with obesity.
Afterward, as part of their pre-bariatric surgery routine, we collected liver biopsies to analyze gene expression changes. Utilizing Gene Set Enrichment Analysis (GSEA), we identified 80 significantly altered pathways linked to crucial functions such as metabolism and immune response. Notably, EPA treatment improved pathways involved in immune functions and lipid metabolism, while it decreased those associated with glucagon signaling.
Our findings underscore the potential of eicosapentaenoic acid to affect metabolic and immune processes in the liver of obese patients. This research paves the way for further exploration of EPA’s benefits and its role in addressing liver conditions associated with obesity.
9
We explored the effectiveness of eicosapentaenoic acid (EPA), a key component of Antarctic krill oil, in battling obesity and its associated liver issues. Our investigation specifically aimed to understand how EPA influences cholesterol levels and overall liver health, especially in the context of diet-induced obesity.
Using a mouse model and analyzing various molecular pathways, we observed that a high-fat diet led to increased oxidative stress and obesity-related indicators, which are harmful to liver function. However, the introduction of EPA showed promising results in reducing oxidative stress, fat accumulation, and improving key metabolic parameters. These improvements were linked to better cholesterol management and support for liver health.
The findings suggest that EPA might serve as a valuable intervention for those struggling with obesity-related liver disease. By enhancing cholesterol metabolism and addressing oxidative stress, EPA could play a role in the prevention and treatment of these conditions. Overall, our results indicate a potential pathway for therapeutic applications in liver health through EPA supplementation.
Using a mouse model and analyzing various molecular pathways, we observed that a high-fat diet led to increased oxidative stress and obesity-related indicators, which are harmful to liver function. However, the introduction of EPA showed promising results in reducing oxidative stress, fat accumulation, and improving key metabolic parameters. These improvements were linked to better cholesterol management and support for liver health.
The findings suggest that EPA might serve as a valuable intervention for those struggling with obesity-related liver disease. By enhancing cholesterol metabolism and addressing oxidative stress, EPA could play a role in the prevention and treatment of these conditions. Overall, our results indicate a potential pathway for therapeutic applications in liver health through EPA supplementation.
7
We explored the effects of eicosapentaenoic acid (EPA) on liver disease in children with biliary atresia (BA), a condition that can lead to severe liver inflammation and fibrosis. Our study focused on patients who underwent laparoscopic Kasai portoenterostomy (lapKP), a surgical procedure aimed at treating BA. We divided participants into two groups: those who received EPA treatment and those who did not.
After two years, we observed that while EPA did not enhance jaundice clearance—meaning it didn’t improve the initial condition—it did help reduce the progression of liver fibrosis in jaundice-free patients. Specifically, those treated with EPA showed lower levels of certain biomarkers that indicate liver damage and a significant improvement in liver function as measured by the Aminotransferase-to-Platelet Ratio Index (APRI).
In summary, although EPA administration did not help with jaundice clearance, it played a beneficial role in slowing down liver fibrosis in these patients over a two-year period. This provides hope for alternative therapies in managing liver health after surgery for biliary atresia.
After two years, we observed that while EPA did not enhance jaundice clearance—meaning it didn’t improve the initial condition—it did help reduce the progression of liver fibrosis in jaundice-free patients. Specifically, those treated with EPA showed lower levels of certain biomarkers that indicate liver damage and a significant improvement in liver function as measured by the Aminotransferase-to-Platelet Ratio Index (APRI).
In summary, although EPA administration did not help with jaundice clearance, it played a beneficial role in slowing down liver fibrosis in these patients over a two-year period. This provides hope for alternative therapies in managing liver health after surgery for biliary atresia.
References
- Uthaiah NM, Venkataramareddy SR, Mudhol S, Sheikh AY. EPA-rich Nannochloropsis oceanica biomass regulates gut microbiota, alleviates inflammation and ameliorates liver fibrosis in rats. Food Res Int. 2025;202:115733. doi:10.1016/j.foodres.2025.115733
- Joerg R, Itariu BK, Amor M, Bilban M, Langer F, et al. The effect of long-chain n-3 PUFA on liver transcriptome in human obesity. Prostaglandins Leukot Essent Fatty Acids. 2024;204:102663. doi:10.1016/j.plefa.2024.102663
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. doi:10.3390/nu16213614
- MacLeod B, Wang C, Brown LH, Borkowski E, Nakamura MT, et al. Fads2 knockout mice reveal that ALA prevention of hepatic steatosis is dependent on delta-6 desaturase activity. J Lipid Res. 2024;65:100642. doi:10.1016/j.jlr.2024.100642
- Sumida W, Tainaka T, Shirota C, Makita S, Amano H, et al. Eicosapentaenoic acid administration ameliorates the progression of liver fibrosis after laparoscopic Kasai portoenterostomy. Pediatr Surg Int. 2024;40:239. doi:10.1007/s00383-024-05800-2
- Sabinari I, Horakova O, Cajka T, Kleinova V, Wieckowski MR, et al. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD. Physiol Res. 2024;73:S295.
- Huang C, Yong Q, Lu Y, Wang L, Zheng Y, et al. Gentiopicroside improves non-alcoholic steatohepatitis by activating PPARα and suppressing HIF1. Front Pharmacol. 2024;15:1335814. doi:10.3389/fphar.2024.1335814
- Wang Y, Hou J, Li X, Chen P, Chen F, et al. Tyrosol regulates hepatic lipid metabolism in high-fat diet-induced NAFLD mice. Food Funct. 2024;15:3752. doi:10.1039/d3fo05345h
- Iizasa S, Nagao K, Tsuge K, Nagano Y, Yanagita T. Identification of genes regulated by lipids from seaweed Susabinori (Pyropia yezoensis) involved in the improvement of hepatic steatosis: Insights from RNA-Seq analysis in obese db/db mice. PLoS One. 2023;18:e0295591. doi:10.1371/journal.pone.0295591
- Hull MA, Ow PL, Ruddock S, Brend T, Smith AF, et al. Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol. BMJ Open. 2023;13:e077427. doi:10.1136/bmjopen-2023-077427
- Videla LA, Valenzuela R, Del Campo A, Zúñiga-Hernández J. Omega-3 Lipid Mediators: Modulation of the M1/M2 Macrophage Phenotype and Its Protective Role in Chronic Liver Diseases. Int J Mol Sci. 2023;24. doi:10.3390/ijms242115528
- Chen YF, Fan ZK, Gao X, Zhou F, Guo XF, et al. n-3 polyunsaturated fatty acids in phospholipid or triacylglycerol form attenuate nonalcoholic fatty liver disease via mediating cannabinoid receptor 1/adiponectin/ceramide pathway. J Nutr Biochem. 2024;123:109484. doi:10.1016/j.jnutbio.2023.109484
- Liu W, Zhu M, Gong M, Zheng W, Zeng X, et al. Comparison of the Effects of Monounsaturated Fatty Acids and Polyunsaturated Fatty Acids on Liver Lipid Disorders in Obese Mice. Nutrients. 2023;15. doi:10.3390/nu15143200
- Rohwer N, Jelleschitz J, Höhn A, Weber D, Kühl AA, et al. Prevention of colitis-induced liver oxidative stress and inflammation in a transgenic mouse model with increased omega-3 polyunsaturated fatty acids. Redox Biol. 2023;64:102803. doi:10.1016/j.redox.2023.102803
- Roque-Jiménez JA, Oviedo-Ojeda MF, Whalin M, Lee-Rangel HA, Relling AE. Ewe early gestation supplementation with eicosapentaenoic and docosahexaenoic acids affects the liver, muscle, and adipose tissue fatty acid profile and liver mRNA expression in the offspring. J Anim Sci. 2023;101. doi:10.1093/jas/skad144
- Zhang Z, Zhou Q, Li Z, Huang F, Mo K, et al. DTX2 attenuates Lenvatinib-induced ferroptosis by suppressing docosahexaenoic acid biosynthesis through HSD17B4-dependent peroxisomal β-oxidation in hepatocellular carcinoma. Drug Resist Updat. 2025;81:101224. doi:10.1016/j.drup.2025.101224
- Zhang D, Wang Z, Wang X, Yue W, Zhang L, et al. Cosupplementation with DHA and medium-chain triglycerides ameliorates NAFLD and reduces amyloid-β accumulation by modulating hepatic lipid metabolism in APP/PS1 mice. Lipids. 2025. doi:10.1002/lipd.12436
- Wang X, Ishimatsu K, Li J, Wen X, Ou W, et al. APT imaging of hepatocellular carcinoma signals an effective therapeutic response in advance of tumor shrinkage. Hepat Oncol. 2024;11:2389031. doi:10.1080/20450923.2024.2389031
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. doi:10.1039/d4fo04961f
- Zhang Y, Zhao Q, Zhao R, Lu Y, Jiang S, et al. Efficacy of DHA-enriched phosphatidylserine and its underlying mechanism in alleviating polystyrene nanoplastics-induced hepatotoxicity in mice. Int Immunopharmacol. 2024;142:113154. doi:10.1016/j.intimp.2024.113154
- Yang J, Félix-Soriano E, Martínez-Gayo A, Ibañez-Santos J, Sáinz N, et al. SIRT1 and FOXO1 role on MASLD risk: effects of DHA-rich n-3 PUFA supplementation and exercise in aged obese female mice and in post-menopausal overweight/obese women. J Physiol Biochem. 2024;80:697. doi:10.1007/s13105-024-01044-9
- Perva IT, Simina IE, Bende R, Motofelea AC, Chirita Emandi A, et al. Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial. Medicina (Kaunas). 2024;60. doi:10.3390/medicina60081366
- Zhang H, Lu Y, Zhang Y, Dong J, Jiang S, et al. DHA-enriched phosphatidylserine ameliorates cyclophosphamide-induced liver injury via regulating the gut-liver axis. Int Immunopharmacol. 2024;140:112895. doi:10.1016/j.intimp.2024.112895
- Guo C, Liu Z, Fan H, Wang H, Zhang X, et al. Nonlinear relationships of circulating polyunsaturated fatty acids with the complications of liver cirrhosis: A prospective, longitudinal cohort study. Clin Nutr. 2024;43:2083. doi:10.1016/j.clnu.2024.07.027
- Alkhouri N, McCarthy D, Bayne AV, Blonquist T, Yurko-Mauro K, et al. The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction-Associated steatotic Liver Disease (MASLD)-A randomised, double-blind, placebo-controlled, parallel-group clinical trial (PUVENAFLD). Aliment Pharmacol Ther. 2024;60:552. doi:10.1111/apt.18149
- Palmina N, Kononikhin A, Chagovets V, Tokareva A, Antipova A, et al. Dietary liposomal complexes change the fatty acid composition of hepatic bioactive phospholipids in F1(C57blxDBA2\6) mice, as shown by a lipidomic approach. Biomater Sci. 2024;12:3956. doi:10.1039/d4bm00431k
- Sotoudeheian M, Azarbad R, Mirahmadi SM. Investigating the correlation between polyunsaturated fatty acids intake and non-invasive biomarkers of liver fibrosis. Clin Nutr ESPEN. 2024;63:46. doi:10.1016/j.clnesp.2024.06.016
- Li X, Liu C, Zhang R, Li Y, Ye D, et al. Biosynthetic deficiency of docosahexaenoic acid causes nonalcoholic fatty liver disease and ferroptosis-mediated hepatocyte injury. J Biol Chem. 2024;300:107405. doi:10.1016/j.jbc.2024.107405
